VYGLXIA
"VYGLXIA" is a trademark owned by Biohaven Therapeutics Ltd., filed at the WIPO on September 13, 2021. It is on file and covers class 5 (Pharmaceuticals).
- Status
- Mixed
- Filed
- September 13, 2021
- Registered
- Not yet
- Expires
- September 13, 2031
- Application no.
- Not recorded
- Registration no.
- 1633064
- Office
- WIPO
- World Intellectual Property Organization
- Mark type
- Trademark
- 1 class
Who owns VYGLXIA
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Biohaven Therapeutics Ltd.
BHVN · British Virgin Islands
Representative
Smart & Biggar LP
Smart & Biggar LP
What the mark covers
The products and services VYGLXIA is filed for, grouped by Nice class.
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes.
About VYGLXIA
Who owns the trademark "VYGLXIA"?
The WIPO trademark "VYGLXIA" is owned by Biohaven Therapeutics Ltd.
What is the status of "VYGLXIA"?
Its status at the WIPO is: mixed.
Get this data via the API
Everything on this page comes from the Signa API. Pull VYGLXIA and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_4b7782bd-cfa8-4814-bd73-5399874232a8
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_4b7782bd-cfa8-4814-bd73-5399874232a8",
"object": "trademark",
"mark_text": "VYGLXIA",
"status": {
"primary": "mixed",
"stage": "mixed"
},
"office_code": "WO",
"application_number": null,
"filing_date": "2021-09-13",
"nice_classes": [
5
],
"owners": [
{
"name": "BIOHAVEN THERAPEUTICS LTD.",
"entity_id": "ent_019eb7d2-fb5b-7654-8bb0-d58ab7c6ce1e"
}
]
}